https://www.biospace.com/all-news All News en-US Thu, 05 Nov 2026 17:19:07 GMT https://www.biospace.com/drug-development/novartis-confirms-9-reported-cases-of-tumors-in-patients-treated-with-zolgensma Heather McKenzie Advocates are sounding the alarm on social media as they learn from their doctors that Novartis has received reports of tumors in patients who have been treated with the spinal muscular atrophy gene therapy. Thu, 05 Nov 2026 17:19:07 GMT https://www.biospace.com/drug-development/novartis-confirms-9-reported-cases-of-tumors-in-patients-treated-with-zolgensma https://www.biospace.com/business/revmeds-rasonque-shatters-analyst-estimates-with-198m-quarter Annalee Armstrong Pent-up demand for the new pancreatic cancer therapy Rasonque helped RevMed soar past analysts’ sales expectations and reach 5,000 patients in the third quarter. Thu, 05 Nov 2026 15:39:43 GMT https://www.biospace.com/business/revmeds-rasonque-shatters-analyst-estimates-with-198m-quarter https://www.biospace.com/drug-development/t-time-british-biotech-pours-133m-into-the-pot-for-bispecifics Gabrielle Masson With backing from three Big Pharma investment arms, British biotech T-Therapeutics is brewing up a clinical launch for its cancer and autoimmune T cell engagers. Thu, 05 Nov 2026 15:01:20 GMT https://www.biospace.com/drug-development/t-time-british-biotech-pours-133m-into-the-pot-for-bispecifics https://www.biospace.com/biospace-layoff-tracker BioSpace Editorial Staff Follow along as BioSpace tracks job cuts and restructuring initiatives. Thu, 05 Nov 2026 14:47:00 GMT https://www.biospace.com/biospace-layoff-tracker https://www.biospace.com/deals/evommune-inks-molecular-glue-deal-worth-1-1b-biobucks-to-fill-pipeline-gap Gabrielle Masson Evommune is commiting $30 million upfront for Hinova Pharmaceuticals’ oral molecular glue degrader—a low-cost bet with a high probability of success, according to analysts, after clinical failures roiled the biotech’s internal pipeline earlier this year. Thu, 05 Nov 2026 13:53:16 GMT https://www.biospace.com/deals/evommune-inks-molecular-glue-deal-worth-1-1b-biobucks-to-fill-pipeline-gap https://www.biospace.com/business/coveted-metabolic-gem-rhythm-reportedly-gets-10b-offer-from-astrazeneca Annalee Armstrong AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech. Thu, 05 Nov 2026 13:32:52 GMT https://www.biospace.com/business/coveted-metabolic-gem-rhythm-reportedly-gets-10b-offer-from-astrazeneca https://www.biospace.com/drug-development/beyond-the-needle-the-future-of-intratumoral-therapy Jennifer C. Smith-Parker BioSpace Insights In this episode of Denatured, you’ll hear from from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies trigger systemic anticancer immunity from a local injection, and redefine a foundational platform in immuno-oncology. Thu, 05 Nov 2026 11:42:40 GMT https://www.biospace.com/drug-development/beyond-the-needle-the-future-of-intratumoral-therapy https://www.biospace.com/career-advice/the-top-12-companies-hiring-in-biopharma-now Angela Gabriel Average jobs live on BioSpace increased year over year in October, a good sign for those eyeing a new position. If that’s you, check out the list of which companies are most actively looking to hire. Thu, 05 Nov 2026 07:01:00 GMT https://www.biospace.com/career-advice/the-top-12-companies-hiring-in-biopharma-now https://www.biospace.com/drug-development/opinion-a-treatment-revolution-is-underway-in-mash David Soergel To build on the momentum in MASH, we—at Madrigal Pharmaceuticals and the industry more widely—must further expand approaches to diagnosis, monitoring and individualized treatment to help more patients. Thu, 05 Nov 2026 05:54:00 GMT https://www.biospace.com/drug-development/opinion-a-treatment-revolution-is-underway-in-mash https://www.biospace.com/job-trends/1-in-5-have-had-multiple-biopharma-layoffs-poll-finds Angela Gabriel Biotech and pharma professionals share job hunt challenges after being let go, while a recruiting expert discusses why hiring managers prefer candidates without employment gaps and how to address gaps in interviews. Thu, 05 Nov 2026 05:01:00 GMT https://www.biospace.com/job-trends/1-in-5-have-had-multiple-biopharma-layoffs-poll-finds https://www.biospace.com/deals/boehringer-bets-big-on-china-offering-7b-biobucks-for-sino-cancer-programs Gabrielle Masson Boehringer Ingelheim is building up its China strategy, inking a deal to develop new cancer treatments with Sino Biopharmaceutical just weeks after opening an R&D facility in Shanghai. Wed, 04 Nov 2026 19:32:28 GMT https://www.biospace.com/deals/boehringer-bets-big-on-china-offering-7b-biobucks-for-sino-cancer-programs https://www.biospace.com/deals/abbvie-bets-up-to-1-47b-for-nxeras-discarded-ibd-program Gabrielle Masson AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing. Wed, 04 Nov 2026 16:10:33 GMT https://www.biospace.com/deals/abbvie-bets-up-to-1-47b-for-nxeras-discarded-ibd-program https://www.biospace.com/business/amgen-starts-maritide-autoinjector-study-as-pivotal-readouts-approach Nick Paul Taylor With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 candidate is tolerable. Meanwhile, the company has begun testing an autoinjector formulation. Wed, 04 Nov 2026 16:01:06 GMT https://www.biospace.com/business/amgen-starts-maritide-autoinjector-study-as-pivotal-readouts-approach https://www.biospace.com/drug-development/sanofis-axing-of-nurix-stat6-program-not-a-target-related-issue Heather McKenzie Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather than the drug class more broadly. Wed, 04 Nov 2026 15:58:02 GMT https://www.biospace.com/drug-development/sanofis-axing-of-nurix-stat6-program-not-a-target-related-issue https://www.biospace.com/business/with-mfn-now-embedded-in-pharma-execs-see-little-impact-from-democrats-blue-wave Annalee Armstrong Speaking on third quarter earnings calls this week, Novo and Pfizer’s CEOs see little change to their Most Favored Nation drug pricing deals, which were signed with the Trump administration last year. Wed, 04 Nov 2026 13:33:26 GMT https://www.biospace.com/business/with-mfn-now-embedded-in-pharma-execs-see-little-impact-from-democrats-blue-wave https://www.biospace.com/business/2026-ipo-stock-tracker-how-biotechs-new-to-public-markets-are-performing Gabrielle Masson BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026. Wed, 04 Nov 2026 12:59:00 GMT https://www.biospace.com/business/2026-ipo-stock-tracker-how-biotechs-new-to-public-markets-are-performing https://www.biospace.com/business/novo-lilly-battle-for-oral-glp-1-dominance-with-data-tit-for-tat Annalee Armstrong Novo CEO Mike Maziar Doustdar insists that his company is ahead of fierce rival Eli Lilly as oral Wegovy rises to 8 million total prescriptions since its January launch. Wed, 04 Nov 2026 12:25:20 GMT https://www.biospace.com/business/novo-lilly-battle-for-oral-glp-1-dominance-with-data-tit-for-tat https://www.biospace.com/business/pfizer-eyes-europe-first-for-lyme-vaccine-as-prevalence-rises-in-us Annalee Armstrong Since Pfizer already owns a tick-borne encephalitis franchise in Europe, the region is a natural first step for the pharma’s upcoming Lyme disease vaccine. Wed, 04 Nov 2026 12:12:00 GMT https://www.biospace.com/business/pfizer-eyes-europe-first-for-lyme-vaccine-as-prevalence-rises-in-us https://www.biospace.com/business/q3-earnings-roll-on-fda-pushes-rare-disease-uniqures-huntingtons-therapy-reaches-review Jef Akst Annalee Armstrong Heather McKenzie Gabrielle Masson The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerating rare disease treatments; HHS greenlights the compounding of six unapproved peptides; and uniQure’s embattled gene therapy for Huntington’s disease has finally been accepted for review. Wed, 04 Nov 2026 11:17:12 GMT https://www.biospace.com/business/q3-earnings-roll-on-fda-pushes-rare-disease-uniqures-huntingtons-therapy-reaches-review https://www.biospace.com/business/how-a-ms-frizzle-esque-librarian-helped-flagships-louisa-helms-find-biotech Annalee Armstrong BioSpace 40 Under 40 honoree Louisa Helms is a lot of things—athlete, scientist, entrepreneur and likely future biotech executive. Just don’t ask her to pick up any pipettes. Wed, 04 Nov 2026 05:54:00 GMT https://www.biospace.com/business/how-a-ms-frizzle-esque-librarian-helped-flagships-louisa-helms-find-biotech